Evaluation of Efficacy and Safety Using oXiris Versus M100 Filter in Pneumonia-induced Acute Kidney Injury Patients Requiring Continuous Renal Replacement Therapy

What this Trial Is About

This research investigates the effectiveness and safety of two different hemofilters, Oxiris and M100, used during Continuous Renal Replacement Therapy (CRRT) in patients with pneumonia-related acute kidney injury (AKI) who also have septic shock. The study aims to compare how well these filters reduce levels of inflammatory markers such as interleukin 6 (IL-6), procalcitonin (PCT), and C-reactive protein (CRP). It also evaluates clinical outcomes including 28-day mortality, ventilator-free days, length of stay in intensive care and hospital, and other safety parameters. Participants are randomly assigned to receive CRRT with either the Oxiris filter or the M100 filter. The intervention lasts for at least 24 hours, during which blood parameters are closely monitored. If the filter clogs within 24 hours, the same type is replaced; if clogging occurs after 24 hours and CRRT is still needed, the M100 filter is used. The treatment continues until signs of kidney recovery appear, such as improved urine output and stable clinical conditions, or a decision is made to switch to intermittent dialysis. During the study, patients undergo blood tests at the start and 24 hours after treatment to measure septic biomarkers and routine biochemistry. Clinical conditions, including use of vasopressors, ventilator-free days, and length of hospital stay, are tracked. Mortality is recorded up to 28 days after ICU admission, with follow-up ensured through multiple contact methods and national registry checks. This comprehensive monitoring aims to assess the relative benefits and risks of each filter type in managing pneumonia-induced AKI with septic shock.

To Compare the Efficacy and Safety of Using oXiris and M100 During CRRT